作者
E Lazzari,Gabriella Rozera,Roberta Gagliardini,Valentina Mazzotta,Lavinia Fabeni,Federica Forbici,Giulia Berno,Enrico Girardi,Andrea Antinori,Fabrizio Maggi,Isabella Abbate
摘要
Background New anti-HIV drugs are coming into use, but little is known about natural resistance to these new compounds, especially as minority variants of the viral quasispecies. The study aimed to detect the presence of amino acid variants related to lenacapavir (LEN) and fostemsavir (FTR) genotypic resistance in the viral quasispecies of antiretroviral naïve primary HIV infections sustained by different HIV-1 subtypes and circulating recombinant forms (CRFs). Methods HIV-1 RNA, from the plasma of 9 naïve to treatment primary HIV infections (Fiebig II n=3, IV n=4, V n=1 and VI n=1), was detected at a median load of 7.2 log copies/ml (IQR: 5.8–7.5). Five subjects harbored HIV subtype B, the remaining ones were infected with subtype F1, CRF02_AG, CRF03_AB, and CRF20_BG. Retro-transcription was carried out with pan-subtype oligonucleotides. Next-generation sequencing of the near-full-length HIV genome was performed on the Illumina platform by fragmentation and sequencing of two long amplicons of 5.5 kilobases (kb) and 3.7 kb generated using pan-subtype primers. Genome reconstruction was obtained with a resequencing strategy using an ad hoc workflow built on the CLC workbench software (Qiagen). HIV variants in the capsid p24 protein (CA) and gp120 coding regions were examined, using the HXB2 amino acid sequence as a reference. Results Near full-length genomes were obtained from nucleotide 781 to 9,174, with a median coverage of 3,524 (IQR: 930–6,520) (figure 1): for gag and env regions, the median coverage was 1,710 (IQR: 750–6,063) and 1,768 (IQR: 871–5,270), respectively. All reconstructed CA encoding regions did not reveal amino acid (aa) mutations in positions known to be related to the emergence of LEN genotypic resistance (i.e., L56, N57, M66, Q67, K70, N74, A105, and T107). Regarding gp120 encoding regions, among the aa positions known to be involved in FTR genotypic resistance in treated subjects (i.e., S375, M426, M434, and M475), we found the M426R variant at a 100% frequency in two HIV subtype B genomes. Such a variant is known as polymorphism, different from the M426L variant, which is associated with high-level drug resistance. Broadening the search to other aa positions associated with low in vitro susceptibility to FTR, we found, in one of the two subjects showing the M426R, the A204T variant at a frequency of 100%. Conclusions Ultra-deep sequencing revealed that, even at the quasispecies level, there exists a strong conservation of the CA aa sequence among different HIV subtypes and CRFs, probably due to the key functional role exerted by this protein. Although the binding region for FTR overlaps the domain involved in CD4 recognition, aa conservation in gp120 was slightly lower. The knowledge of aa motives, which are more prone to mutate in nature, could help in the timely recognition of emerging drug resistance during new drug therapy administration. Clinical data in drug-exposed populations should confirm this model information.